Associated Papers
Molecular pathology and computational profiling of Janus kinase 2 (JAK2) mutation in acute lymphoblastic leukemia: insights from a Pakistani cohort.
Maqsood S et al.
Laboratory Medicine, 2025
Clinical and genetic profile of Chinese patients with indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract.
Chen H et al.
Neoplasia (new York, N.y.), 2024
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L et al.
Cancers, 2019
31766351 (PubMed )
Supplement: cancers-11-01833-s001.zip › Supplementary_Table_3.xlsx › Tabelle1
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M et al.
Cancer Cell, 2019
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S et al.
Blood, 2018
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.
Nairismägi ML et al.
Leukemia, 2016
26854024 (PubMed )
Supplement: leu201613x3.xls › ST8
Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
López C et al.
British Journal of Haematology, 2016
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC et al.
Nature Genetics, 2015
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C et al.
Haematologica, 2015
Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.
Kawashima-Goto S et al.
International Journal of Hematology, 2015
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
Bergmann AK et al.
Genes, Chromosomes & Cancer, 2014
Select a paper to view details